Skip to content

Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

Coronary Artery Disease | ST Elevation Myocardial Infarction | Coronary Artery Stenosis | Acute Myocardial...

Beta-blockers have the greatest cardiovascular impact in patients with reduced heart function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In patients without these high-risk features treated with coronary artery bypass graft (CABG) surgery, their continued long-term role is unclear.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Age ≥ 18 years treated with index isolated CABG
* Able to consent to study
* On beta blocker therapy at the 6-8week visit
* LV systolic function (≥45% assessed within 6months of CABG date)

Exclusion Criteria:

* Prior heart failure with reduced ejection fraction (LVEF \<45%)
* Pre- or peri-operative atrial fibrillation or flutter
* Peri-CABG stroke
* Unable to follow-up

Lieu de l'étude

Royal University Hospital
Royal University Hospital
Saskatoon, Saskatchewan
Canada

Contactez l'équipe d'étude

Primary Contact

Jay Shavadia, MD

[email protected]
3069862260
Étude parrainée par
University of Saskatchewan
Participants recherchés
Plus d'informations
ID de l'étude: NCT04788186